EnteroMedics Inc. (EnteroMedics) is a development-stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity, its associated co-morbidities, and other gastrointestinal disorders. The Company’s neuroblocking technology, which it refers to as VBLOC therapy, is designed to intermittently block the vagus nerve using high-frequency, low-energy and electrical impulses. The Company’s product under development is the Maestro System, which uses VBLOC therapy to limit the expansion of the stomach, helps control hunger sensations between meals, reduces the frequency and intensity of stomach contractions, and produces a feeling of early and prolonged fullness. As of December 31, 2008, the Company was evaluating the Maestro System in human clinical trials conducted in the United States, Australia, Mexico, Norway and Switzerland.